Cited by 204Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.

A role for tau at the synapse in Alzheimer’s disease pathogenesis

Pooler, Amy M., Noble, Wendy, Hanger, Diane P.·2014·Neuropharmacology

DOI 10.1016/j.neuropharm.2013.09.018

Open this paper in CoChat — free account

Abstract

Alzheimer's disease (AD) is characterized by brain deposition of amyloid plaques and tau neurofibrillary tangles along with steady cognitive decline. Although the mechanism by which AD pathogenesis occurs is unclear, accumulating evidence suggests that dysfunction and loss of synaptic connections may be an early event underlying disease progression. Profound synapse degeneration is observed in AD, and the density of these connections strongly correlates with cognitive ability. Initial investigations into AD-related synaptic changes focused on the toxic effects of amyloid. However, recent research suggests an emerging role for tau at the synapse. Even in the absence of tangles, mice overexpressing human tau display significant synaptic degeneration, suggesting that soluble, oligomeric tau is the synaptotoxic species. However, the localization of tau within synapses in both healthy and AD brains indicates that tau might play a role in normal synaptic function, which may be disrupted in disease. Tau is able to impact synaptic activity in several ways: studies show tau interacting directly with post-synaptic signaling complexes, regulating glutamatergic receptor content in dendritic spines, and influencing targeting and function of synaptic mitochondria. Early trials of tau-targeted immunotherapy reduce tau pathology and synapse loss, indicating that the toxic effects of tau may be reversible within a certain time frame. Understanding the role of tau in both normal and degenerating synapses is crucial for the development of therapeutic strategies designed to ameliorate synapse loss and prevent AD pathogenesis. This article is part of the Special Issue entitled 'The Synaptic Basis of Neurodegenerative Disorders'.

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2013.09.018

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work.
Buée, L., Bussière, T., Buée‐Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,142
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Domain Interaction Between NMDA Receptor Subunits and the Postsynaptic Density Protein PSD-95
Kornau, H., Schenker, L. T., Kennedy, M. B., & Seeburg, P. H. (1995) · Science · doi:10.1126/science.7569905 · Cited by 1,916

Show all 121 references

Sorted by citations

Alzheimer disease
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Tau Kinetics in Neurons and the Human Central Nervous System
Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586
Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies
Rawat, P., Sehar, U., Bisht, J., Selman, A., Culberson, J., & Reddy, P. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112841 · Cited by 509
The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
Savio, L. E. B., de Andrade Mello, P., da Silva, C. G., & Coutinho-Silva, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00052 · Cited by 437
Synaptic Impairment in Alzheimer’s Disease: A Dysregulated Symphony
Forner, S., Baglietto-Vargas, D., Martini, A. C., Trujillo-Estrada, L., & LaFerla, F. M. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.04.002 · Cited by 430
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo, M. J., Devous, M. D., Navitsky, M., Lu, M., Salloway, S., Schaerf, F. W., Jennings, D., Arora, A. K., McGeehan, A., Lim, N. C., et al. (2017) · Brain · doi:10.1093/brain/aww334 · Cited by 357
Exercise, cognitive function, and aging
Barnes, J. N. (2015) · AJP Advances in Physiology Education · doi:10.1152/advan.00101.2014 · Cited by 314
Neuroinflammation in Alzheimer’s disease
Zhang, F., & Jiang, L. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75546 · Cited by 276
Alzheimer's disease and type 2 diabetes: a critical assessment of the shared pathological traits
Chatterjee, S., & Mudher, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00383 · Cited by 270
Tau immunotherapy for Alzheimer's disease
Pedersen, J. T., & Sigurdsson, E. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.003 · Cited by 247
Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease
Overk, C. R., & Masliah, E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.015 · Cited by 242
The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases
Wu, M., Zhang, M., Yin, X., Chen, K., Hu, Z., Zhou, Q., Cao, X., Chen, Z., & Liu, D. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00270-1 · Cited by 241
It’s all about tau
Tapia‐Rojas, C., Cabezas-Opazo, F., Deaton, C. A., Vergara, E. H., Johnson, G. V. W., & Quintanilla, R. A. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.005 · Cited by 207
Alzheimer’s disease as a synaptopathy: Evidence for dysfunction of synapses during disease progression
Meftah, S., & Gan, J. (2023) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2023.1129036 · Cited by 205
Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia
Bereczki, E., Francis, P. T., Howlett, D., Pereira, J. B., Höglund, K., Bogstedt, A., Cedazo‐Minguez, A., Baek, J., Hortobágyi, T., Attems, J., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.04.005 · Cited by 167
Autophagy in the presynaptic compartment in health and disease
Vijayan, V., & Verstreken, P. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201611113 · Cited by 170
Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers
Quinn, J. P., Corbett, N. J., Kellett, K. A. B., & Hooper, N. M. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-170959 · Cited by 170
The Theta Rhythm of the Hippocampus: From Neuronal and Circuit Mechanisms to Behavior
Núñez, Á., & Buño, W. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.649262 · Cited by 183
Synaptic Change in the Posterior Cingulate Gyrus in the Progression of Alzheimer's Disease
Scheff, S. W., PRICE, D. A., Ansari, M. A., Roberts, K. N., Schmitt, F. A., Ikonomović, M. D., & Mufson, E. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141518 · Cited by 169
The role of extracellular Tau in the spreading of neurofibrillary pathology
Medina, M., & Avila, J. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00113 · Cited by 161
Oxytocin receptors are expressed on dopamine and glutamate neurons in the mouse ventral tegmental area that project to nucleus accumbens and other mesolimbic targets
Peris, J., MacFadyen, K. A., Smith, J. A., de Kloet, A. D., Wang, L. A., & Krause, E. G. (2016) · The Journal of Comparative Neurology · doi:10.1002/cne.24116 · Cited by 158
C‐terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease
Vos, A. D., Jacobs, D., Struyfs, H., Fransén, E., Andersson, K., Portelius, E., Andréasson, U., Surgeloose, D. D., Hernalsteen, D., Sleegers, K., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.012 · Cited by 158
Metals and Neuronal Metal Binding Proteins Implicated in Alzheimer’s Disease
Cristóvão, J. S., Santos, R., & Gomes, C. M. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9812178 · Cited by 146
Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer’s disease: An integrative review
Millan, M. J. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.004 · Cited by 151
NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer's disease
Corsetti, V., Florenzano, F., Atlante, A., Bobba, A., Ciotti, M. T., Natale, F., Della Valle, F., Borreca, A., Manca, A., Meli, G., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv059 · Cited by 129
Magnesium Protects Cognitive Functions and Synaptic Plasticity in Streptozotocin-Induced Sporadic Alzheimer’s Model
Xu, Z.-P., Li, L., Bao, J., Wang, Z.-H., Zeng, J., Liu, E.-J., Li, X., Huang, R., Gao, D., Li, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108645 · Cited by 129
Synaptic Dysfunction in Alzheimer’s Disease: Aβ, Tau, and Epigenetic Alterations
Li, K., Wei, Q., Liu, F., Hu, F., Xie, A., Zhu, L., & Liu, D. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0533-3 · Cited by 121
Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer’s Pathogenesis
Penke, B., Szűcs, M., & Bogár, F. (2020) · Molecules · doi:10.3390/molecules25071659 · Cited by 119
P2X7 Receptor as a Therapeutic Target
Marchi, E. D., Orioli, E., Ben, D. D., & Adinolfi, E. (2016) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2015.11.004 · Cited by 117
Neuronal Network Oscillations in Neurodegenerative Diseases
Nimmrich, V., Draguhn, A., & Axmacher, N. (2015) · NeuroMolecular Medicine · doi:10.1007/s12017-015-8355-9 · Cited by 110
Insights into Disease-Associated Tau Impact on Mitochondria
Szabo, L., Eckert, A., & Grimm, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176344 · Cited by 107
Synaptic activity and Alzheimer's disease: a critical update
Tampellini, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00423 · Cited by 110
Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer’s disease –conformist, nonconformist, and realistic prospects for AD pathogenesis
Li, H., Liu, C.-C., Zheng, H., & Huang, T. Y. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0139-3 · Cited by 103
Acetylation as a major determinant to microtubule-dependent autophagy: Relevance to Alzheimer's and Parkinson disease pathology
Esteves, A. R., Palma, A. M., Gomes, R., Santos, D., Silva, D. F., & Cardoso, S. M. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.11.014 · Cited by 105
The associations between Parkinson’s disease and cancer: the plot thickens
Feng, D. D., Cai, W., & Chen, X. M. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0043-z · Cited by 103
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
New Features about Tau Function and Dysfunction
Medina, M., Hernández, F., & Ávila, J. (2016) · Biomolecules · doi:10.3390/biom6020021 · Cited by 103
Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer’s disease
Lau, D. H. W., Hogseth, M., Phillips, E. C., O’Neill, M. J., Pooler, A. M., Noble, W. J., & Hanger, D. P. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0317-4 · Cited by 93
Self-citation
CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer’s Disease
Shentu, Y.-P., Huo, Y., Feng, X.-L., Gilbert, J., Zhang, Q., Liuyang, Z.-Y., Wang, X.-L., Wang, G., Zhou, H., Wang, X.-C., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.009 · Cited by 90
In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment
Vanhaute, H., Ceccarini, J., Michiels, L., Koole, M., Sunaert, S., Lemmens, R., Triau, E., Emsell, L., Vandenbulcke, M., & Van Laere, K. (2020) · Neurology · doi:10.1212/wnl.0000000000009818 · Cited by 88
Impact of sleep disturbances on neurodegeneration: Insight from studies in animal models
Owen, J. E., & Veasey, S. C. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104820 · Cited by 91
Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment
Ma, J., Huo, X., Jarpe, M. B., Kavelaars, A., & Heijnen, C. J. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0604-3 · Cited by 73
Oligomeric α‐synuclein and β‐amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases
Williams, S. M., Schulz, P., & Sierks, M. R. (2015) · European Journal of Neuroscience · doi:10.1111/ejn.13056 · Cited by 71
Extrasynaptic NMDA receptor-induced tau overexpression mediates neuronal death through suppressing survival signaling ERK phosphorylation
Sun, X., Tuo, Q., Liuyang, Z., Xie, A., Feng, X.-L., Yan, X., Qiu, M., Shen, L., Wang, X.-L., Cao, F.-Y., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.329 · Cited by 71
Dissecting Complex and Multifactorial Nature of Alzheimer’s Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective
Talwar, P., Sinha, J., Grover, S., Rawat, C., Kushwaha, S. S., Agarwal, R., Taneja, V., & Kukreti, R. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9390-0 · Cited by 71
Visual system manifestations of Alzheimer's disease
Kusne, Y. N., Wolf, A. B., Townley, K., Conway, M. D., & Peyman, G. A. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13319 · Cited by 74
Tau-induced pathology in epilepsy and dementia: notions from patients and animal models.
Sánchez, M., García-Cabrero, A., Sánchez-Elexpuru, G., Burgos, D., & Serratosa, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041092 · Cited by 68
Crocin-protected malathion-induced spatial memory deficits by inhibiting TAU protein hyperphosphorylation and antiapoptotic effects
Mohammadzadeh, L., Abnous, K., Razavi, B. M., & Hosseinzadeh, H. (2019) · Nutritional Neuroscience · doi:10.1080/1028415x.2018.1492772 · Cited by 67
Competitive electrochemical immunosensor for the detection of unfolded p53 protein in blood as biomarker for Alzheimer’s disease
Amor-Gutiérrez, O., Costa‐Rama, E., Varas, N. A., Martínez-Rodríguez, C., Novelli, A., Fernández‐Sánchez, M. T., & Costa‐García, A. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.09.042 · Cited by 67
Reversal of LTP-Like Cortical Plasticity in Alzheimer’s Disease Patients with Tau-Related Faster Clinical Progression
Koch, G., Lorenzo, F. D., Fernández‐del‐Olmo, M., Bonnı̀, S., Ponzo, V., Caltagirone, C., Bozzali, M., & Martorana, A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150813 · Cited by 68
Exosomal tau with seeding activity is released from Alzheimer's disease synapses, and seeding potential is associated with amyloid beta
Miyoshi, E., Bilousova, T. V., Melnik, M., Fakhrutdinov, D., Poon, W. W., Vinters, H. V., Miller, C. A., Corrada, M. M., Kawas, C. H., Bohannan, R. C., et al. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00644-z · Cited by 69
Ca2+-permeable AMPA receptor: A new perspective on amyloid-beta mediated pathophysiology of Alzheimer's disease
Whitehead, G., Regan, P. L., Whitcomb, D. J., & Cho, K. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.022 · Cited by 64
Iron Pathophysiology in Alzheimer’s Diseases
Wang, T., Xu, S.-F., Fan, Y.-G., Li, L.-B., & Guo, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-9589-5_5 · Cited by 64
Intracellular and Extracellular Roles for Tau in Neurodegenerative Disease
Hanger, D. P., Lau, D. H. W., Phillips, E. C., Bondulich, M. K., Guo, T., Woodward, B. W., Pooler, A. M., & Noble, W. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132054 · Cited by 66
Self-citation
Functional Integrity of Synapses in the Central Nervous System of Cognitively Intact Individuals with High Alzheimer’s Disease Neuropathology Is Associated with Absence of Synaptic Tau Oligomers
Singh, A., Allen, D., Fracassi, A., Tumurbaatar, B., Natarajan, C., Scaduto, P., Woltjer, R., Kayed, R., Limon, A., Krishnan, B., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200716 · Cited by 56
Tau and spectraplakins promote synapse formation and maintenance through Jun kinase and neuronal trafficking
Voelzmann, A., Okenve-Ramos, P., Qu, Y., Chojnowska-Monga, M., del Caño-Espinel, M., Prokop, A., & Sánchez‐Soriano, N. (2016) · eLife · doi:10.7554/elife.14694 · Cited by 56
Dendritic spines are lost in clusters in Alzheimer’s disease
Mijalkov, M., Volpe, G., Fernaud-Espinosa, I., DeFelipe, J., Pereira, J. B., & Merino‐Serrais, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-91726-x · Cited by 56
PET Imaging for Early Detection of Alzheimer’s Disease
Bao, W., Jia, H., Finnema, S. J., Cai, Z., Carson, R. E., & Huang, Y. H. (2017) · PET Clinics · doi:10.1016/j.cpet.2017.03.001 · Cited by 54
Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to
Henriques, A. D., Benedet, A. L., Camargos, E. F., Rosa‐Neto, P., & Nóbrega, O. D. T. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.01.002 · Cited by 56
Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer’s disease and other tauopathies
Florenzano, F., Corsetti, V., Ciasca, G., Ciotti, M. T., Pittaluga, A., Olivero, G., Feligioni, M., Iannuzzi, F., Latina, V., Sciacca, M. F. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17371 · Cited by 54
Environmental lead exposure aggravates the progression of Alzheimer's disease in mice by targeting on blood brain barrier
Wu, S., Liu, H., Zhao, H., Wang, X., Chen, J., Xia, D., Chen, X., Cheng, J., Zhao, Z., & He, Y. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.11.009 · Cited by 51
Associations of monoamine oxidase A gene first exon methylation with sexual abuse and current depression in women
Checknita, D., Ekström, T. J., Comasco, E., Nilsson, K. W., Tiihonen, J., & Hodgins, S. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1875-3 · Cited by 50
Behavioral Abnormalities in Knockout and Humanized Tau Mice
Gonçalves, R. A., Wijesekara, N., Fraser, P. E., & Felice, F. G. D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00124 · Cited by 52
c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer’s Diseases
Rehfeldt, S. C. H., Majolo, F., Goettert, M. I., & Laufer, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249677 · Cited by 47
Sex Differences and Effects of Predictive Cues on Delayed Punishment Discounting
Liley, A. E., Gabriel, D. B. K., Sable, H. J. K., & Simon, N. W. (2019) · eNeuro · doi:10.1523/eneuro.0225-19.2019 · Cited by 48
Cannabis as a Gateway Drug for Opioid Use Disorder
Williams, A. R. (2020) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110520935338 · Cited by 47
Genistein attenuates amyloid-beta-induced cognitive impairment in rats by modulation of hippocampal synaptotoxicity and hyperphosphorylation of Tau
Petry, F. D. S., Hoppe, J. B., Klein, C. P., dos Santos, B. G., Hözer, R. M., Bifi, F., Matté, C., Salbego, C. G., & Trindade, V. M. T. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108525 · Cited by 46
Long Non-coding RNA: Insight Into Mechanisms of Alzheimer's Disease
Lan, Z., Chen, Y., Jin, J., Xu, Y., & Zhu, X. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.821002 · Cited by 45
Tau pathology is associated with synaptic density and longitudinal synaptic loss in Alzheimer’s disease
Wang, J., Huang, Q., Chen, X., You, Z., He, K., Guo, Q., Huang, Y. H., Yang, Y., Lin, Z., Guo, T., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02501-z · Cited by 46
Structural studies on the mechanism of protein aggregation in age related neurodegenerative diseases
Eftekharzadeh, B., Hyman, B. T., & Wegmann, S. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.03.001 · Cited by 44
N-terminal tau truncation in the pathogenesis of Alzheimer's disease (AD): Developing a novel diagnostic and therapeutic approach
Amadoro, G., Latina, V., Corsetti, V., & Calissano, P. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165584 · Cited by 44
Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer’s disease models
Corsetti, V., Borreca, A., Latina, V., Giacovazzo, G., Pignataro, A., Krashia, P., Natale, F., Cocco, S., Rinaudo, M., Malerba, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa039 · Cited by 42
Microglia Degrade Extracellular Tau Oligomers Deposits via Purinergic P2Y12-Driven Podosomes, Filopodia Formation and Induce Chemotaxis
Chinnathambi, S., & Das, R. R. (2021) · Cell & Bioscience · doi:10.1186/s13578-023-01028-0 · Cited by 45
Thermodynamics of the Interaction between Alzheimer's Disease Related Tau Protein and DNA
Camero, S., Benítez, M. J., Cuadros, R., Hernández, F., Ávila, J., & Jiménez, J. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104690 · Cited by 40
Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer¿s disease correlates with pathology
Rosenberger, A. F. N., Rozemüller, A. J. M., van der Flier, W. M., Scheltens, P., van der Vies, S. M., & Hoozemans, J. J. M. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0079-9 · Cited by 40
Olfactory bulbectomy in mice triggers transient and long-lasting behavioral impairments and biochemical hippocampal disturbances
Almeida, R. F., Ganzella, M., Machado, D. G., Loureiro, S. O., Leffa, D. T., Quincozes‐Santos, A., Pettenuzzo, L. F., Duarte, M. M. M. F., Duarte, T., & Souza, D. O. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.02.013 · Cited by 41
Biological substrates of addiction
Joffe, M. E., Grueter, C. A., & Grueter, B. A. (2014) · Wiley Interdisciplinary Reviews Cognitive Science · doi:10.1002/wcs.1273 · Cited by 42
Emerging targets in drug discovery against neurodegenerative diseases: Control of synapsis disfunction by the RhoA/ROCK pathway
Martín-Cámara, O., Cores, Á., López‐Alvarado, P., & Menéndez, J. C. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113742 · Cited by 39
The propagation mechanisms of extracellular tau in Alzheimer’s disease
Wei, Y., Liu, M., & Wang, D. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10573-y · Cited by 40
Tau Pathology Promotes the Reorganization of the Extracellular Matrix and Inhibits the Formation of Perineuronal Nets by Regulating the Expression and the Distribution of Hyaluronic Acid Synthases
Li, Y., Li, Z., Jin, T., Wang, Z., & Zhao, P. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160804 · Cited by 38
Tau aggregates improve the Purinergic receptor P2Y12-associated podosome rearrangements in microglial cells
Chinnathambi, S., Das, R. R., & Desale, S. E. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2023.119477 · Cited by 37
Small molecule modulation of the p75 neurotrophin receptor inhibits multiple amyloid beta-induced tau pathologies
Yang, T., Tran, K. C., Zeng, A. Y., Massa, S. M., & Longo, F. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-77210-y · Cited by 40
Dendritic/Post-synaptic Tau and Early Pathology of Alzheimer’s Disease
Yin, X., Zhao, C., Qiu, Y., Zhou, Z., Bao, J., & Qian, W. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.671779 · Cited by 41
Overactivation of NR 2B‐containing NMDA receptors through entorhinal–hippocampal connection initiates accumulation of hyperphosphorylated tau in rat hippocampus after transient middle cerebral artery occlusion
Xu, C., Liu, A., Chen, J., Pan, Z., Wan, Q., Li, Z., & Wang, Z. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13134 · Cited by 35
A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca2+ homeostasis in 3xTg-AD mice
Li, T., Jiao, J., Su, Q., Hölscher, C., Zhang, J., Yan, X., Zhao, H., Cai, H.-Y., & Qi, J. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108042 · Cited by 36
Ongoing Research on the Role of Gintonin in the Management of Neurodegenerative Disorders
Ikram, M. A., Ullah, R., Khan, A., & Kim, M. O. (2020) · Cells · doi:10.3390/cells9061464 · Cited by 36
Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice
Paes-Colli, Y., Aguiar, A. F. L., Isaac, A. R., Ferreira, B. K., Campos, R. M. P., Trindade, P. M. P., Reis, R. A. D. M., & Sampaio, L. D. S. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.917164 · Cited by 39
Can magnesium reduce central neurodegeneration in Alzheimer's disease? Basic evidences and research needs
Toffa, D. H., Magnerou, M. A., Kassab, A., Djibo, F. H., & Sow, A. D. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.03.014 · Cited by 33
Role of P2X7 and P2Y 2 receptors on α-secretase-dependent APP processing: Control of amyloid plaques formation “ in vivo ” by P2X7 receptor
Miras‐Portugal, M. T., Díaz‐Hernandéz, J. I., Gómez‐Villafuertes, R., Dı́az-Hernández, M., Artalejo, A. R., & Gualix, J. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.02.005 · Cited by 33
Pharmacological Modulators of Tau Aggregation and Spreading
Dominguez‐Meijide, A., Vasili, E., & Outeiro, T. F. (2020) · Brain Sciences · doi:10.3390/brainsci10110858 · Cited by 36
The Synaptic Vesicle Protein 2A Interacts With Key Pathogenic Factors in Alzheimer’s Disease: Implications for Treatment
Kong, Y., Huang, L., Li, W., Liu, X., Zhou, Y., Liu, C., Zhang, S., Xie, F., Zhang, Z., Jiang, D., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.609908 · Cited by 29
Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs
Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27
Friend or foe: role of pathological tau in neuronal death
Wu, M., Chen, Z., Jiang, M. H., Bao, B., Li, D., Yin, X., Wang, X., Liu, D., & Zhu, L. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02024-z · Cited by 28
The interplay between age at menopause and synaptic integrity on Alzheimer’s disease risk in women
Alexander, M. W., Honer, W. G., Saloner, R., Galea, L. A. M., Bennett, D. A., Rabin, J. S., & Casaletto, K. B. (2025) · Science Advances · doi:10.1126/sciadv.adt0757 · Cited by 32
Challenges in the treatment of Alzheimer’s disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors
Kuo, Y., & Rajesh, R. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1621750 · Cited by 27
Differential effects of ischemic vascular disease and Alzheimer’s disease on brain atrophy and cognition
Zheng, L., Vinters, H. V., Mack, W. J., Weiner, M. W., Chui, H. C., & for the IVD program project (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.152 · Cited by 27
Cuscutae Japonicae Semen Ameliorates Memory Dysfunction by Rescuing Synaptic Damage in Alzheimer’s Disease Models
Ju, I. G., Kim, N., Choi, J. G., Lee, J. K., & Oh, M. S. (2019) · Nutrients · doi:10.3390/nu11112591 · Cited by 24
Genome-wide association study of brain biochemical phenotypes reveals distinct genetic architecture of Alzheimer’s disease related proteins
Oatman, S. R., Reddy, J. S., Quicksall, Z., Carrasquillo, M. M., Wang, X., Liu, C., Yamazaki, Y., Nguyen, T., Malphrus, K. G., Heckman, M. G., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00592-2 · Cited by 27
Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer’s Disease
Williams, S. M., Schulz, P., Rosenberry, T. L., Caselli, R. J., & Sierks, M. R. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161116 · Cited by 24

Authors: Pooler, A. M., Noble, W., & Hanger, D. P.
Affiliations: King's College London (GB)
Corresponding author: Hanger, Diane P.
ORCID: Pooler, Amy M.
Noble, Wendy
Hanger, Diane P.
Venue: Neuropharmacology
Publisher: Elsevier BV
Published: 2014-01
Volume: 76
Pages: 1-8
ISSN: 0028-3908 (ISSN-L)
DOI: 10.1016/j.neuropharm.2013.09.018
OpenAlex: W1972886222
Cited by: 203
References: 121
Citations by year: 2026: 8 · 2025: 14 · 2024: 10 · 2023: 15 · 2022: 16 · 2021: 17 · 2020: 20 · 2019: 20 · 2018: 18 · 2017: 13 · 2016: 20 · 2015: 15 · 2014: 15
FWCI: 1.91
Type: journal article
Language: en
Open access: closed
Locations: Neuropharmacology (publishedVersion)
PubMed (publishedVersion)
Research Portal (King's College London) (submittedVersion)
Funders: Wellcome Trust
Medical Research Council
Biotechnology and Biological Sciences Research Council
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: tau protein, Alzheimer's disease, synaptic degeneration, tau oligomers, synaptotoxicity, synaptic mitochondria, glutamate receptors, dendritic spines, cognitive decline
MeSH terms: Alzheimer Disease, Animals, Humans, Mitochondria, Models, Neurological, Nerve Degeneration, Nerve Tissue Proteins, Synaptic Transmission, Signal Transduction, Amyloid beta-Peptides, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A role for tau at the synapse in Alzheimer’s disease pathogenesis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks